Relapsing Multiple Sclerosis Clinical Trial
Official title:
Secondary Use of Data Study Characterizing Kesimpta (Ofatumumab) Onboarding and Utilization in RMS Patients Using MSGo, With a Non-interventional Primary Use of Data Sub-study Comparing Patient Reported Outcomes Relative to Clinical Outcomes (EAFToS)
This is a non-interventional primary use of data study utilizing de-identified patient-level onboarding and adherence data managed through the MSGo patient support service platform and includes a sub-study to explore the impact of ofatumumab on relevant patient reported outcomes (PROs) with respect to clinical outcomes.
This study will be run in two parts. Part I will operate as a Secondary Use of Data study and Part II will operate as a Non-Interventional primary use of data study. Part I: This study is descriptive in nature without any key underlying hypothesis and will explore the onboarding and adherence of RMS patients in Australia to ofatumumab treatment. De-identified patient-level onboarding and adherence data will be primarily generated and managed through the MSGo platform which will function as a Patient Support Service. Part II: This part of the study will operate as a non-interventional primary use of data study and will explore the impact of ofatumumab on relevant patient reported outcomes (PROs) with respect to clinical outcomes. This part of the study will only be conducted at a selection of participating clinics. Patients in this part of the study will also have data collected as part of Part I of the study. The data for the PROs will be collected through a mobile based application . ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04121065 -
Role of ADA SNPs in Subjects With Relapsing Multiple Sclerosis (RMS)
|
||
| Active, not recruiting |
NCT03996291 -
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT04510220 -
9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
|
Phase 3 | |
| Terminated |
NCT02241785 -
Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis (MS) After Failure on Other Therapies
|
Phase 4 | |
| Completed |
NCT02792218 -
Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT01412333 -
A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT03257358 -
A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg Fingolimod
|
Phase 4 | |
| Completed |
NCT01628393 -
Efficacy and Safety Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT04626921 -
A Multi-Center, Open-Label Long-Term Extension Study of CNM-Au8 In Patients With Stable Relapsing Multiple Sclerosis
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT02234869 -
Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
|
Phase 4 | |
| Withdrawn |
NCT05077956 -
Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
|
||
| Active, not recruiting |
NCT04486716 -
A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT04121403 -
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)
|
Phase 3 | |
| Recruiting |
NCT05809986 -
Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
|
||
| Terminated |
NCT00988052 -
A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease Course
|
Phase 3 | |
| Active, not recruiting |
NCT05232825 -
A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis
|
Phase 3 | |
| Terminated |
NCT01047319 -
A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT04847596 -
A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
|
||
| Completed |
NCT01006941 -
Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety Study
|
Phase 2 | |
| Completed |
NCT01127750 -
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients
|
Phase 3 |